Lupus Miliaris Disseminatus Faciei: Not Only a Facial Dermatosis

Schaarschmidt, Marthe‐Lisa; Schlich, Michèle; Staub, Janina; Schmieder, Astrid; Goerdt, Sergij; Peitsch, Wiebke K.

doi:10.2340/00015555-2616

Cited by 9 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Isotretinoin may modulate sebum production, keratinocytes proliferation and differentiation, in addition to its immunomodulating activity, hence its efficacy in KD (Rademaker, 2013). Clearing of the lesions of face and scalp lesions with some residual scars was noted, but the axillary lesions remained (Schaarschmidt et al, 2017). Anatomical response to isotretinoin may be an explanation to this response, for further affirmative studies.…”

Section: Kyrle's Diseasementioning

confidence: 87%

“…A 28‐year‐old male patient with a 3‐month history of facial and extra facial lupus miliaris disseminatus lesions started on isotretinoin 30 mg/day (0.4 mg/kg) for 1 year with regular laboratory monitoring. Clearing of the lesions of face and scalp lesions with some residual scars was noted, but the axillary lesions remained (Schaarschmidt et al, ). Anatomical response to isotretinoin may be an explanation to this response, for further affirmative studies.…”

Section: Indications Of Low‐dose Isotretinoin In Dermatologymentioning

confidence: 99%

See 1 more Smart Citation

Low dose of isotretinoin: A comprehensive review

Abdelmaksoud

Lotti

Anadolu

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Isotretinoin is a first‐generation retinoid initially approved for the treatment of severe cases of acne vulgaris (nodulocystic acne). Because of its broad anti‐inflammatory and immunomodulatory properties, it has been used beyond its initial approval in a myriad of other indications. Adverse effects of isotretinoin vary from xerosis to teratogenicity. Herein, we reviewed the literature, through date‐unlimited PubMed search, from inception till December 2019, using the following search terms: “low‐dose isotretinoin” and “dermatology,” “isotretinoin and safety,” “isotretinoin, off‐label uses,” “isotretinoin and male fertility,” “isotretinoin, iPLEDGE system,” aiming to deliver a therapeutic update relevant to clinical practice. All English‐language articles were considered with no limitation based on the articles' type. Low‐dose isotretinoin is not limited to old and novel dermatological conditions, but also showed promising results in the field of infertility and safety in the field of gastroenterology. We also highlight on the safety profile of the drug and experts' recommendations to enhance safety measures to decrease fetal risk while on isotretinoin.

show abstract

Section: Kyrle's Diseasementioning

confidence: 87%

Section: Indications Of Low‐dose Isotretinoin In Dermatologymentioning

confidence: 99%

Low dose of isotretinoin: A comprehensive review

Abdelmaksoud

Lotti

Anadolu

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Its exact etiopathogenesis remains unclear. Various hypotheses have believed it to be a form of cutaneous tuberculosis, tuberculid, sarcoidosis, and granulomatous rosacea, but research failed to support these associations [6]. LMDF is distinguished from granulomatous rosacea by the lack of erythema and telangiectasia and by the presence of caseating necrosis in the granulomas [5].…”

Section: Discussionmentioning

confidence: 99%

Lupus miliaris disseminatus faciei: A report with a new dermoscopy finding

Kumar¹,

Savitha²

2021

Our Dermatol Online

View full text Add to dashboard Cite

Lupus miliaris disseminatus faciei (LMDF) is a rare inflammatory disorder characterized by asymptomatic papular lesions mainly over the central part of the face, common in young adults and with a spontaneously resolving course. Its exact etiology remains unknown, its treatment is problematic, and there is a lack of controlled studies on LMDF. Histopathology shows dermal epithelioid granulomas with central necrosis and surrounding lymphocytic infiltrate with multinucleate giant cells. Dermoscopic findings published show discrete focal orangish structureless areas located around follicular openings with whitish keratotic plugs. Herein, we report a case of LMDF with dermoscopy showing stellate scar signs and structureless white areas.

show abstract

“…Until now, the standard treatment strategies of LMDF remains unclear. Minocycline, glucocorticoid, isotretinoin, clofazimine, tranilast, cyclosporine, and so on have been reported to be effective (Cymerman, Rosenstein, Shvartsbeyn, Meehan, & Kornreich, ; Sardana, Chugh, Ranjan, & Khurana, ; Schaarschmidt et al, ). Besides, LMDF was recently proved to respond to topical dapsone gel therapy (Ferguson & Fearfield, ).…”

Section: Case Reportmentioning

confidence: 99%

Case report: A successful combined treatment of severe lupus miliaris disseminatus faciei with oral isotretinoin and methylprednisolone

Yin

Sun

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Lupus miliaris disseminates faciei (LMDF) is a rare inflammatory dermatosis characterized by an asymptomatic papular eruption in the central face, of which the etiology and pathogenesis are not clear. There is a lack of standard treatment recommendations, especially for severe cases. Here we report a new case of successful treatment of severe LMDF by the combination therapy of oral isotretinoin and methylprednisolone.

show abstract

Lupus Miliaris Disseminatus Faciei: Not Only a Facial Dermatosis

Cited by 9 publications

References 13 publications

Low dose of isotretinoin: A comprehensive review

Low dose of isotretinoin: A comprehensive review

Lupus miliaris disseminatus faciei: A report with a new dermoscopy finding

Case report: A successful combined treatment of severe lupus miliaris disseminatus faciei with oral isotretinoin and methylprednisolone

Contact Info

Product

Resources

About